Skip to search formSkip to main contentSkip to account menu

NCX1000

Known as: NCX 1000, NCX-1000 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Expression of Concern and Corrections
EDITORIAL EXPRESSION OF CONCERN. PNAS is publishing an Editorial Expression of Concern regarding the following three articles: (i… 
2008
2008
S1903 Beneficial Effects of UDCA and Ncx-1000 Alone or in Combination with Vitamin E in a Nonalcoholic Steatohepatitis Rat Model
2008
2008
276 PRELIMINARY EFFICACY AND SAFETY OF REPEATED ORAL DOSES OF NCX-1000 FOR THE TREATMENT OF PORTAL HYPERTENSION. A DOUBLE-BLIND, PROOF OF CONCEPT, DOSE ESCALATING STUDY
2007
2007
Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity.
Nonalcoholic steatohepatitis (NASH) is a common and potentially severe form of liver disease. This study aimed to determine the… 
Review
2006
Review
2006
Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.
Portal hypertension, a life threatening complication of liver cirrhosis, results from increased intrahepatic resistance and… 
2004
2004
NCX-1000: a liver-specific NO donor
Recent advances in the knowledge of the pathophysiology of portal hypertension show that cirrhotic liver exhibits endothelial… 
2003
2003
A New Synthetic Method of NCX-1000
  • C. Li
  • 2003
  • Corpus ID: 101997759
To improve the reported synthetic route of NCX 1000 Using ferulic acid and 1,4 dibromobutane as the starting materials to prepare… 
2002
2002
11 P An no-derivative of UDCA (NCX-1000) modulates the dinamic component of intrahepatic resistance in a rat model of liver chirrosis
Highly Cited
2001
Highly Cited
2001
An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity
Caspases are key mediators in liver inflammation and apoptosis. In the present study we provide evidence that a nitric oxide (NO… 
2001
2001
NCX-1000, an NO derivative of UDCA, refeases NO and protects against portal hypertension by inhibiting hepatic stellate cell contraction
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)